Cantor Fitzgerald Reaffirms “Overweight” Rating for Structure Therapeutics (NASDAQ:GPCR)

Cantor Fitzgerald reiterated their overweight rating on shares of Structure Therapeutics (NASDAQ:GPCR) in a research report report published on Thursday, Benzinga reports. The brokerage currently has a $65.00 price objective on the stock.

Other research analysts have also issued reports about the company. BMO Capital Markets upped their price target on Structure Therapeutics from $83.00 to $100.00 and gave the company an outperform rating in a research report on Friday, June 7th. JPMorgan Chase & Co. initiated coverage on Structure Therapeutics in a research report on Tuesday, May 21st. They set an overweight rating and a $65.00 price target on the stock. Finally, JMP Securities dropped their price target on Structure Therapeutics from $91.00 to $86.00 and set a market outperform rating on the stock in a research report on Friday, August 9th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of Buy and an average target price of $84.63.

Structure Therapeutics Stock Up 1.7 %

Shares of NASDAQ GPCR opened at $37.12 on Thursday. Structure Therapeutics has a 12 month low of $25.57 and a 12 month high of $75.02. The company has a market cap of $1.73 billion, a price-to-earnings ratio of -48.21 and a beta of -3.52. The business has a fifty day simple moving average of $40.24 and a 200-day simple moving average of $40.52.

Structure Therapeutics (NASDAQ:GPCR) last announced its earnings results on Thursday, August 8th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.05. As a group, sell-side analysts expect that Structure Therapeutics will post -0.94 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Squarepoint Ops LLC increased its position in Structure Therapeutics by 4.5% in the 2nd quarter. Squarepoint Ops LLC now owns 14,449 shares of the company’s stock worth $567,000 after purchasing an additional 617 shares during the last quarter. Sandia Investment Management LP acquired a new position in Structure Therapeutics in the 2nd quarter worth about $39,000. Brandywine Managers LLC increased its position in Structure Therapeutics by 9.2% in the 4th quarter. Brandywine Managers LLC now owns 12,007 shares of the company’s stock worth $489,000 after purchasing an additional 1,007 shares during the last quarter. Quarry LP acquired a new position in Structure Therapeutics in the 2nd quarter worth about $79,000. Finally, Teachers Retirement System of The State of Kentucky increased its position in Structure Therapeutics by 17.8% in the 1st quarter. Teachers Retirement System of The State of Kentucky now owns 13,733 shares of the company’s stock worth $589,000 after purchasing an additional 2,077 shares during the last quarter. 91.78% of the stock is owned by institutional investors and hedge funds.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.